Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 2635 • 2018 ACR/ARHP Annual Meeting
Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus
Saika Sharmeen¹, Katalin Banki² and Andras Perl³, ¹Medicine, State University of New York Upstate Medical University, Syracuse, NY, ²Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune hypercoagulable state caused by antiphospholipid antibodies (aPL) which represent a diagnostic criterion and underlie significant comorbidities in…
Abstract Number: 156 • 2018 ACR/ARHP Annual Meeting
Assessing the Role of Ascvd Score in Primary Thrombosis Prophylaxis Strategy Among Asymptomatic Antiphospholipid Antibody Carriers
Yu Zuo¹, Akrithi Udupa², Jennifer Fan¹, Una E. Makris¹, David Karp^1,3 and Yu-min Shen¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Primary thrombosis prophylaxis among asymptomatic antiphospholipid antibody (aPL) carriers is challenging. The presence of aPL does not always lead to thromboembolic events. Additional factors…
Abstract Number: 2641 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity
Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Hiromi Shimada, Mikiya Kato, Taichi Miyagi, Kiyo Ueeda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: To find the effect of HCQ treatment on expression of S100 proteins which were reported to reflect the activity of SLE including lupus nephritis…
Abstract Number: 157 • 2018 ACR/ARHP Annual Meeting
Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients
Yu Zuo¹, Chun Li², Song Zhang³, Una Makris¹, David Karp⁴ and Zhan-Guo Li⁵, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Peking University People's Hospital, Beijing, China, ³University of Texas Southwestern Medical Center, dallas, TX, ⁴Rheumatology, UT Southwestern Med Ctr, Dallas, TX, ⁵Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Risk stratification of asymptomatic aPL carriers is difficult. Our objective was to identify additional clinical and epidemiological predictors of arterial thrombosis, venous thrombosis, and…
Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Matthew J. Koster¹, Melissa Snyder², Michel Villatoro-Villar¹, Cynthia S. Crowson³, Tanaz A. Kermani⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…
Abstract Number: 159 • 2018 ACR/ARHP Annual Meeting
The Frequency of Screening and Prevalence of Antiphospholipid Antibodies in the General Population
Giordano Egiziano¹, Jessica Widdifield², Anisur Rahman³, Evelyne Vinet⁴, Cristiano S. Moura⁵, Jeffrey R. Curtis⁶ and Sasha Bernatsky⁷, ¹Department Medicine, McGill University, Montreal, QC, Canada, ²University Health Network, Toronto, ON, Canada, ³Rayne Institute, University College London, London, United Kingdom, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵The Centre for Outcomes Research and Evaluation (CORE), McGill University Health Centre, Montreal, QC, Canada, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The antiphospholipid syndrome (APS) is defined by vascular thrombosis or pregnancy morbidity in the presence of persistently circulating antiphospholipid antibodies (aPL). Those positive for…
Abstract Number: 2893 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study
Savino Sciascia¹, Jinoos Yazdany², Maria Jose Cuadrado³, Massimo Radin⁴, Maria Dall'Era², Ishita Aggarwal⁵, Roberta Fenoglio⁶, Antonella Barreca⁷, Mauro Papotti⁷, Irene Cecchi⁸, Elena Rubini⁹, Karen Schreiber¹⁰ and Dario Roccatello⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²University of California, San Francisco, San Francisco, CA, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁷University of Turin, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ¹⁰Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom
Background/Purpose: Renal vascular involvement is an important prognostic marker of lupus nephritis (LN). Among patients with various vascular changes, individuals with thromboticmicroangiopathy (TMA) present with…
Abstract Number: 163 • 2018 ACR/ARHP Annual Meeting
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Item Reduction Survey
Medha Barbhaiya¹, Stephane Zuily², Yasaman Ahmadzadeh³, Raymond P. Naden⁴, Karen Costenbader⁵ and Doruk Erkan⁶, ¹Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Université de Lorraine, CHRU Nancy, Nancy, France, ³Hospital for Special Surgery, New York, NY, ⁴New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Background/Purpose: An international multidisciplinary effort has been initiated to develop new rigorous, consensus-based criteria to identify patients with high likelihood of having APS. The methodological…
Abstract Number: 164 • 2018 ACR/ARHP Annual Meeting
Reliability of Lupus Anticoagulant and Anti-Phosphatidylserine/Prothrombin Autoantibodies in Antiphosphospholipid Syndrome: A Multicenter Study
Massimo Radin¹, Irene Cecchi², Elena Rubini³, Anna Scotta⁴, Roberta Rolla⁵, Barbara Montaruli⁶, Patrizia Pergolini⁵, Giulio Mengozzi⁴, Elena Muccini⁴, Antonella Vaccarino⁷, Dario Roccatello⁸ and Savino Sciascia⁹, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴University of Turin, Turin, Italy, ⁵University of Turin, Novara, Italy, ⁶Ospedale Mauriziano, Turin, Italy, ⁷Ospedale S. Giovanni Bosco, Turin, Italy, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Correct interpretation of lupus anticoagulant (LA) tests is crucial for diagnosis of antiphospholipid syndrome (APS). However, testing patients during vitamin K antagonist (VKA) or…
Abstract Number: 166 • 2018 ACR/ARHP Annual Meeting
Superior Sensitivity for Detection of Primary Antiphospholipid Syndrome By a 9-Test Panel in Patients with Deep Venous Thrombosis, Pulmonary Embolism, and Stroke or Transient Ischemic Attack
Konrad Dziamski¹, Katalin Banki² and Andras Perl³, ¹Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by thrombotic events mediated by antiphospholipid antibodies (aPL). Most patients have primary APS (PAPS), while a significant minority has…
Abstract Number: 167 • 2018 ACR/ARHP Annual Meeting
Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Following an Initial Venous or Arterial Thromboembolic Event
Tom Ortel¹, Sreelatha Meleth², Diane Catellier², Mark Crowther³, Doruk Erkan⁴, Paul R. Fortin⁵, David Garcia⁶, Nana Haywood², Steven R. Levine⁷, Michael J. Phillips² and Nedra Whitehead², ¹Duke University, Durham, NC, ²RTI International, Research, Triangle Park, NC, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁵Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ⁶Hematology, University of Washington Medical Center, Seattle, WA, ⁷Neurology, State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: After an initial thromboembolic event (TE), several studies reported that patients with antiphospholipid syndrome (APS) manifest a high-risk for recurrent TE. A systematic review…
Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Elena Rubini³, Ana Suárez⁴, Dario Roccatello⁵, Savino Sciascia⁶ and Javier Rodríguez-Carrio⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…
Abstract Number: 170 • 2018 ACR/ARHP Annual Meeting
Predictive Value of Antiphospholipid Antibodies in the Acute Phase of Deep Vein Thrombosis
Katja Perdan Pirkmajer¹, Anja Boc², Saša Čučnik³, Alenka Mavri⁴, Polona Žigon³, Eva Podovsovnik⁵, Monika Štalc⁶, Nina Vene⁷ and Ales Ambrozic⁸, ¹Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Medicine, Institute of Anatomy, University of Ljubljana, Ljubljana, Slovenia, ³University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia, ⁴University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁵Faculty for Tourism Studies, University of Primorska, Portoroz, Slovenia, ⁶Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁷Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Background/Purpose: Deep vein thrombosis (DVT) is frequent and potentially life threatening disease with tendency to reoccur. Anticoagulant treatment of the first episode of DVT usually…
Abstract Number: 1271 • 2017 ACR/ARHP Annual Meeting
Associations between Systemic Lupus Susceptibility (SLE) Loci and Anti-Phospholipid Antibody (aPL) Positivity in Childhood-Onset SLE (cSLE)
Linda T Hiraki^1,2, France Gagnon³, Earl Silverman², Deborah M. Levy², Sima Abu Alsaoud⁴ and Karl Everett^1,3, ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Genome-wide association studies have identified nearly 60 susceptibility loci for systemic lupus erythematosus (SLE). However, few studies have investigated their influence on specific disease…
Abstract Number: 1292 • 2017 ACR/ARHP Annual Meeting
Long-Term Follow-up of 320 Chilren Born to Mothers with Systemic Autoimmune Diseases: A Multicentre Survey from 24 Rheumatology Centers in Italy
Maria Grazia Lazzaroni¹, Cecilia Nalli¹, Laura Andreoli¹, Chiara Carini¹, Marilia Rodrigues², Francesca Dall'Ara¹, Elena Bartoloni-Bocci³, Roberto Gerli³, Maria Gerosa⁴, Cecilia B. Chighizola⁵, Pier Luigi Meroni⁴, Luigi Sinigaglia⁶, Paola Conigliaro⁷, Roberto Perricone⁷, Ada Corrado⁸, Francesco Paolo Cantatore⁸, Salvatore D'Angelo⁹, Ignazio Olivieri⁹, Maria Favaro¹⁰, Maddalena Larosa¹⁰, Andrea Doria¹⁰, Amelia Ruffatti¹¹, Elena Generali¹², Carlo Selmi¹³, Marianna Meroni¹⁴, Maurizio Cutolo¹⁵, Melissa Padovan¹⁶, Marcello Govoni¹⁶, Giulia Pazzola¹⁷, Carlo Salvarani¹⁸, Susanna Peccatori¹⁹, Giuseppe Paolazzi¹⁹, Imma Prevete²⁰, Giovanni Minisola²⁰, Gian Domenico Sebastiani²¹, Antonio Brucato²², Véronique Ramoni²³, Roberto Caporali²⁴, Carlomaurizio Montecucco²⁴, Viola Signorini²⁵, Chiara Tani²⁶, Marta Mosca²⁵, Marica Trevisani²⁷, Nazzarena Malavolta²⁷, Marta Vadacca²⁸, Antonella Afeltra²⁹, Ester Vivaldelli³⁰, Armin Maier³⁰, Elisa Visalli³¹, Rosario Foti³¹, Carolina Benigno³², Lucia Zuliani³³, Armando Gabrielli³³, Corrado Campochiaro³⁴, Elena Baldissera³⁵, Maria Grazia Sabbadini³⁶, Nicoletta Romeo³⁷ and Angela Tincani¹, ¹University and Spedali Civili of Brescia, Brescia, Italy, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³University and Azienda Ospedaliera of Perugia, Perugia, Italy, ⁴Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁵Rheumatology, Istituto Auxologico Italiano, University of Milan, Cusano Milanino, Italy, ⁶Istituto Ortopedico Gaetano Pini, University of Milan, Italy, Milan, Italy, ⁷Policlinico Tor Vergata of Rome, Rome, Italy, ⁸Ospedali Riuniti of Foggia, Foggia, Italy, ⁹San Carlo Hospital of Potenza, Potenza, Italy, ¹⁰University and Azienda Ospedaliera of Padova, Padova, Italy, ¹¹Unità di Reumatologia, Dipartimento di Medicina-DIMED, Università di Padova., Padova, Italy, ¹²Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ¹³Humanitas Research Hospital of Milan, Rozzano, Italy, ¹⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ¹⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ¹⁶UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ¹⁷Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico of Reggio-Emilia, Reggio-Emilia, Italy, ¹⁸Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy, ¹⁹Azienda Provinciale Servizi Sanitari of Trento, Trento, Italy, ²⁰Azienda Ospedaliera San Camillo of Rome, Roma, Italy, ²¹Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ²²Struttura Complessa Medicina Interna, ASST Papa Giovanni XXIII, Bergamo, Italy, ²³Ospedale Papa Giovanni XXIII of Bergamo, Policlinico San Matteo of Pavia, Bergamo, Pavia, Italy, ²⁴University and Policlinico San Matteo of Pavia, Pavia, Italy, ²⁵University of Pisa, Pisa, Italy, ²⁶Rheumatology Unit, University of Pisa, Pisa, Italy, ²⁷Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy, ²⁸University Campus Biomedico of Rome, Roma, Italy, ²⁹University Campus Biomedico of Rome, roma, Italy, ³⁰Ospedale of Bolzano, Bolzano, Italy, ³¹Policlinico Vittorio Emanuele-Ferrarotto-Bambin Gesù of Catania, Catania, Italy, ³²University Federico II of Napoli, Napoli, Italy, ³³Ospedali Riuniti of Ancona, Ancona, Italy, ³⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ³⁵Ospedale San Raffaele of Milan, Milan, Italy, ³⁶Unit of Medicine and Clinical Immunology, Ospedale San Raffaele of Milano, Milan, Italy, ³⁷Ospedale S.Croce e Carle of Cuneo, Cuneo, Italy
Background/Purpose: Rheumatic Diseases (RD) frequently affect women during reproductive age, therefore counseling on family planning is crucial for their quality of life. Children's outcome is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.